EA202192460A1 - Синтетические нейромодуляторные пептиды - Google Patents

Синтетические нейромодуляторные пептиды

Info

Publication number
EA202192460A1
EA202192460A1 EA202192460A EA202192460A EA202192460A1 EA 202192460 A1 EA202192460 A1 EA 202192460A1 EA 202192460 A EA202192460 A EA 202192460A EA 202192460 A EA202192460 A EA 202192460A EA 202192460 A1 EA202192460 A1 EA 202192460A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
synthetic
neuromodulator
neuromodulatory
depression
Prior art date
Application number
EA202192460A
Other languages
English (en)
Inventor
Антон Малышев
Игорь Доронин
Геннадий Бабкин
Аскар Кучумов
Original Assignee
Лактокор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лактокор, Инк. filed Critical Лактокор, Инк.
Publication of EA202192460A1 publication Critical patent/EA202192460A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Abstract

Описана фармацевтическая композиция, содержащая синтетический нейромодулирующий пептид. Изобретение раскрывает нейромодуляторные пептиды, как определено в формуле изобретения, и способы использования таких молекул для терапевтического применения. Было обнаружено, что нейромодулирующие пептиды, включенные в композицию, эффективны при лечении депрессии и других эмоциональных расстройств, включая тревогу.
EA202192460A 2019-03-14 2020-03-13 Синтетические нейромодуляторные пептиды EA202192460A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818458P 2019-03-14 2019-03-14
PCT/US2020/022623 WO2020186155A2 (en) 2019-03-14 2020-03-13 Synthetic neuromodulatory peptides

Publications (1)

Publication Number Publication Date
EA202192460A1 true EA202192460A1 (ru) 2021-11-24

Family

ID=72427118

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192460A EA202192460A1 (ru) 2019-03-14 2020-03-13 Синтетические нейромодуляторные пептиды

Country Status (7)

Country Link
US (1) US20220175873A1 (ru)
EP (1) EP3938375A4 (ru)
CN (1) CN113573723A (ru)
AU (1) AU2020239245A1 (ru)
CA (1) CA3133242A1 (ru)
EA (1) EA202192460A1 (ru)
WO (1) WO2020186155A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3175267A1 (en) * 2020-04-15 2021-10-21 Anton MALYSHEV Synthetic peptides for modulating the metabotropic glutamate receptor 5
WO2023212662A2 (en) * 2022-04-28 2023-11-02 Oregon Health & Science University Compositions and methods for modulating antigen binding activity
CN114916463A (zh) * 2022-05-18 2022-08-19 山东中医药大学 一种实验动物焦虑三联复合行为检测装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194254A (ja) * 1992-01-22 1993-08-03 Banyu Pharmaceut Co Ltd エンドセリンアンタゴニストを含有する抗高脂血症剤
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
JP5188731B2 (ja) * 2007-03-02 2013-04-24 雪印メグミルク株式会社 ペプチド
RU2678987C2 (ru) * 2017-04-28 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Пептид для лечения болезни альцгеймера

Also Published As

Publication number Publication date
CN113573723A (zh) 2021-10-29
US20220175873A1 (en) 2022-06-09
EP3938375A4 (en) 2022-12-21
CA3133242A1 (en) 2020-09-17
EP3938375A2 (en) 2022-01-19
WO2020186155A3 (en) 2020-10-22
WO2020186155A2 (en) 2020-09-17
AU2020239245A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
EA202192460A1 (ru) Синтетические нейромодуляторные пептиды
MX2022013517A (es) Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas.
EA202091709A1 (ru) Ингибиторы днк-пк
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201591501A1 (ru) Терапевтические средства на основе csf-1
EA202090871A1 (ru) Ингибирование убиквитин-специфической пептидазы 30
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
EA201500783A1 (ru) Способы получения дикетопиперазинов и соединений, содержащих дикетопиперазины
EA202091708A1 (ru) Ингибиторы днк-пк
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
EA202191280A1 (ru) Конструкции для доставки для трансцитоза и связанные способы
EA202190888A1 (ru) Пептид для применения в косметике
CY1123623T1 (el) Θεραπεια νευρολογικων νοσων
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EA201792269A1 (ru) Полипептиды, нацеленные на слияние вич
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его